Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FY 2000 FDA appropriations

This article was originally published in The Tan Sheet

Executive Summary

House-Senate conference committee on FY 2000 Agriculture appropriations agrees to set FDA budget at about $1.19 bil., below the level approved by the House but above that passed by the Senate (1"The Tan Sheet" Aug. 9, In Brief). The overall appropriations measure has not come out of conference yet, however, as the committee has stood in recess since Sept. 22, stalled by disagreements over agricultural issues. No date has been set for resuming negotiations

You may also be interested in...



FDA budget

Agency would receive funding of $1.18 bil. and be allowed to collect $145.4 mil. in user fees under Senate Agriculture appropriations bill passed by voice vote Aug. 4. The bill (S 1233) provides total Ag funding of $68.1 bil. The Center for Food Safety & Applied Nutrition would receive $264.8 mil., while the Center for Drug Evaluation and Research would receive $309 mil. in funding for FY 2000. Both allocations fall below the House and the Clinton Administration's requests of $266 mil. and $316.8 mil., respectively. WIC would receive $4.04 bil. in funding for the year

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090355

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel